IMST-28. NON-INVASIVE IMMUNE MONITORING FOLLOWING DC VACCINATION EFFECTIVELY DELINEATES IMMUNE RESPONSES IN GLIOBLASTOMA
Antonios J, Soto H, Everson R, Orpilla J, Shin N, Nathanson D, Harris R, Sadeghi S, Ellingson B, Liau L, Prins R. IMST-28. NON-INVASIVE IMMUNE MONITORING FOLLOWING DC VACCINATION EFFECTIVELY DELINEATES IMMUNE RESPONSES IN GLIOBLASTOMA. Neuro-Oncology 2016, 18: vi92-vi92. DOI: 10.1093/neuonc/now212.384.Peer-Reviewed Original ResearchDC vaccinesImmune monitoringFACS analysisPD-1Immune monitoring of patientsActivated tumor-infiltrating lymphocytesDC vaccine treatmentTumor-infiltrating lymphocytesImmunocompetent C57BL/6 miceMAb-treated miceTumor-bearing hemisphereGL261 glioma cellsPET signal intensityActive lymphocytic infiltrationImmunotherapy fieldMonitoring of patientsMedian survivalStandard chemotherapyClinically relevant modalityMeasures of immune responseNeedle biopsyLymphocytic infiltrationTreated miceLymphocyte responsesNon-invasiveIMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES
Everson R, Shin N, Antonios J, Soto H, Tucker A, Zaretsky J, Orpilla J, Rathe S, Popescu F, Largaespada D, Liau L, Prins R. IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES. Neuro-Oncology 2016, 18: vi99-vi99. DOI: 10.1093/neuonc/now212.412.Peer-Reviewed Original ResearchAutologous tumor lysateTumor-infiltrating lymphocytesTumor-specific mutationsDC vaccinesDendritic cellsCD8+ T cell responsesEnhanced T cell infiltrationTumor-infiltrating lymphocyte culturesImmune responseIntracranial GL261 gliomasT cell infiltrationT cell responsesPhase III trialsTreatment groupsRelevant target antigensMurine glioma cell lineDC therapyTCR clonotypesTumor lysateGL261 gliomasIII trialsNeoantigen peptidesOriginal tumorGlioma cell linesLymphocytic infiltration